INVZ vs. DNA

In the year-to-date period, INVZ achieves a -45.83% return, which is significantly lower than DNA's -29.23% return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current INVZ Sharpe Ratio is -0.17, which is higher than the DNA Sharpe Ratio of -0.63. The chart below compares the historical Sharpe Ratios of INVZ and DNA, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Neither INVZ nor DNA has paid dividends to shareholders.

The maximum INVZ drawdown since its inception was -96.06%, roughly equal to the maximum DNA drawdown of -99.10%. Use the drawdown chart below to compare losses from any high point for INVZ and DNA.

Innoviz Technologies Ltd. (INVZ) and Ginkgo Bioworks Holdings, Inc. (DNA) have volatilities of 26.63% and 25.78%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Innoviz Technologies Ltd. and Ginkgo Bioworks Holdings, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.